These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 37090727)

  • 61. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
    Osipov A; Saung MT; Zheng L; Murphy AG
    J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
    Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
    J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer.
    Cascone T; Fradette J; Pradhan M; Gibbons DL
    Cold Spring Harb Perspect Med; 2022 May; 12(5):. PubMed ID: 34580079
    [TBL] [Abstract][Full Text] [Related]  

  • 64. New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Corke L; Sacher A
    Curr Oncol; 2021 Dec; 29(1):38-55. PubMed ID: 35049678
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Burned-Out CD8
    Sanmamed MF; Nie X; Desai SS; Villaroel-Espindola F; Badri T; Zhao D; Kim AW; Ji L; Zhang T; Quinlan E; Cheng X; Han X; Vesely MD; Nassar AF; Sun J; Zhang Y; Kim TK; Wang J; Melero I; Herbst RS; Schalper KA; Chen L
    Cancer Discov; 2021 Jul; 11(7):1700-1715. PubMed ID: 33658301
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients.
    Hwang I; Kim JW; Ylaya K; Chung EJ; Kitano H; Perry C; Hanaoka J; Fukuoka J; Chung JY; Hewitt SM
    J Transl Med; 2020 Nov; 18(1):443. PubMed ID: 33228719
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
    Zhang X; Shi X; Zhao H; Jia X; Yang Y
    Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer.
    Suzuki J; Tsuboi M; Ishii G
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):169-182. PubMed ID: 34904919
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients.
    Baci D; Cekani E; Imperatori A; Ribatti D; Mortara L
    Front Immunol; 2022; 13():914890. PubMed ID: 35874749
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
    Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
    J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response.
    Lin CY; Huang KY; Kao SH; Lin MS; Lin CC; Yang SC; Chung WC; Chang YH; Chein RJ; Yang PC
    Sci Adv; 2023 Apr; 9(14):eade9944. PubMed ID: 37027467
    [TBL] [Abstract][Full Text] [Related]  

  • 75. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
    Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.
    Chen Y; Chen Z; Chen R; Fang C; Zhang C; Ji M; Yang X
    Future Oncol; 2022 May; 18(14):1757-1775. PubMed ID: 35232247
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.
    Trefny MP; Rothschild SI; Uhlenbrock F; Rieder D; Kasenda B; Stanczak MA; Berner F; Kashyap AS; Kaiser M; Herzig P; Poechtrager S; Thommen DS; Geier F; Savic S; Jermann P; Alborelli I; Schaub S; Stenner F; Früh M; Trajanoski Z; Flatz L; Mertz KD; Zippelius A; Läubli H
    Clin Cancer Res; 2019 May; 25(10):3026-3034. PubMed ID: 30765392
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer.
    Zhang M; Yang W; Wang P; Deng Y; Dong YT; Liu FF; Huang R; Zhang P; Duan YQ; Liu XD; Lin D; Chu Q; Zhong B
    Nat Commun; 2020 Nov; 11(1):6119. PubMed ID: 33257678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.